Eli Lilly and Company (BVMF:LILY34)

Market Cap	3.62T
Revenue (ttm)	290.19B
Net Income (ttm)	75.19B
Shares Out	n/a
EPS (ttm)	83.33
PE Ratio	48.16
Forward PE	27.05
Dividend	0.74 (0.55%)
Ex-Dividend Date	Aug 14, 2025

Volume	18,526
Average Volume	19,539
Open	134.43
Previous Close	134.43
Day's Range	134.01 - 137.25
52-Week Range	113.00 - 180.70
Beta	0.47
RSI	51.94
Earnings Date	Oct 30, 2025

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1876
• Employees: 47,000
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: LILY34

Financial Performance

In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.

Financial numbers in USD